InMed PharmaceuticalsINM
Market Cap: $2.44M
About: InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
Employees: 13
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
6.05% less ownership
Funds ownership: 11.32% [Q1] → 5.27% (-6.05%) [Q2]
22% less funds holding
Funds holding: 18 [Q1] → 14 (-4) [Q2]
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
53% less capital invested
Capital invested by funds: $249K [Q1] → $117K (-$133K) [Q2]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Research analyst outlook
We haven’t received any recent analyst ratings for INM.